DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.72
-0.08 (-1.18%)
As of 3:09PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close6.80
Open6.88
Bid6.72 x 900
Ask6.72 x 800
Day's Range6.68 - 7.05
52 Week Range6.19 - 31.42
Volume350,081
Avg. Volume621,537
Market Cap283.052M
Beta (3Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-4.91
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.29
Trade prices are not sourced from all markets
  • Markityesterday

    See what the IHS Markit Score report has to say about Dermira Inc.

    # Dermira Inc ### NASDAQ/NGS:DERM View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $1.04 billion over the last one-month into ETFs that hold DERM are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
    American City Business Journals8 days ago

    At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

    As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.

  • Markit27 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    # Dermira Inc ### NASDAQ/NGS:DERM View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Neutral Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding DERM are favorable, with net inflows of $986 million. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Do Hedge Funds Love Dermira Inc (DERM)?
    Insider Monkey29 days ago

    Do Hedge Funds Love Dermira Inc (DERM)?

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in October due to various reasons. Nevertheless, the data show elite investors’ consensus picks have done well on average over the long-term. The top 30 S&P 500 stocks among hedge funds at […]

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold DERM had net inflows of $837 million over the last one-month.

  • GlobeNewswirelast month

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on December 10, 2018, the company granted inducement awards to four new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 2,575 shares of Dermira common stock and stock options to purchase an aggregate of 14,100 shares of Dermira common stock.

  • Is Dermira Inc’s (NASDAQ:DERM) CEO Paid At A Competitive Rate?
    Simply Wall St.last month

    Is Dermira Inc’s (NASDAQ:DERM) CEO Paid At A Competitive Rate?

    Tom Wiggans has been the CEO of Dermira Inc (NASDAQ:DERM) since 2010. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $274 million.

  • GlobeNewswire2 months ago

    Dermira to Present at Evercore ISI HealthCONx Conference

    MENLO PARK, Calif., Nov. 19, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DERM earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Dermira Inc Earnings Call

  • GlobeNewswire2 months ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Nov. 08, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of 20.20% and -10.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire2 months ago

    Dermira Reports Third Quarter 2018 Financial Results

    Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to.

  • GlobeNewswire3 months ago

    Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018

    MENLO PARK, Calif., Oct. 31, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • GlobeNewswire3 months ago

    Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the completion of patient enrollment in the Phase 2b dose-ranging study evaluating its anti-IL13 monoclonal antibody, lebrikizumab, in patients with moderate-to-severe atopic dermatitis. The company expects to announce topline efficacy and safety results from the study by early April 2019. “For many living with moderate-to-severe atopic dermatitis, the condition can often be debilitating, with patients finding limited treatment options that are effective at addressing the underlying cause of the disease,” said Luis Peña, chief development officer of Dermira.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.77 billion over the last one-month into ETFs that hold DERM are not among the highest of the last year and have been slowing.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $5.36 billion.